RxDoctor Payments Data

Amy Jones, APRN

Family · Oxford, CTNPI 1962956623

Payments from drug & device makers

$2,791in general payments, 2019–2025

Across 166 payments — averaging $16.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • GSK$425
  • Novo Nordisk$349
  • Abbott$161
  • Pfizer$110
  • Lilly USA, LLC$64
  • plus $387 from 11 others

What the payments were for

  • Food & beverage$2,791100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,791 in reported general payments places this provider in the 85th percentile of 1,596 family providers in Connecticut.

See all family providers in Connecticut

Medicare billing

Part B allowed, 2024
$53,381
Medicare patients
161
Services billed
774

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin25$31,194
MounjaroTirzepatide21$29,415
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$28,999
EliquisApixaban32$28,648
OzempicSemaglutide19$24,096
JanuviaSitagliptin Phosphate18$23,843
TradjentaLinagliptin14$21,432
TrulicityDulaglutide18$18,495
GemtesaVibegron14$15,607
FarxigaDapagliflozin Propanediol16$10,437
LinzessLinaclotide19$10,300
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$6,101
SymbicortBudesonide/Formoterol Fumarate12$2,561
Atorvastatin Calcium325$2,434
Omeprazole130$1,998

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$37$52,62639 claims
Lilly USA, LLCMounjaro, Trulicity$64$47,91039 claims
GSKTrelegy Ellipta$425$28,99946 claims
PfizerEliquis$110$28,64832 claims
Novo NordiskOzempic$349$24,09619 claims
MerckJanuvia$58$23,84318 claims
Sumitomo Pharma America, Inc.Gemtesa$39$15,60714 claims
AstraZenecaFarxiga, Symbicort$15$12,99828 claims
AbbVieLinzess, Synthroid$1,294$11,74735 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,596 family providers in Connecticut.

Other family in Oxford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →